MedTrace Logo

A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine

NCT06113692 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1169

Last updated 2025-08-01

No results posted yet for this study

Summary

The main goal of this study is to describe the clinical course, outcomes and risk factors for myocarditis and pericarditis associated with Moderna vaccination targeting SARS-CoV-2.

Conditions

  • Myocarditis, Pericarditis

Interventions

BIOLOGICAL

mRNA-1273

intramuscular injection

Sponsors & Collaborators

  • Julius Clinical Research

    collaborator UNKNOWN

  • ModernaTX, Inc.

    lead INDUSTRY

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-31
Primary Completion
2024-08-31
Completion
2025-06-30

Countries

  • Denmark
  • Norway
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06113692 on ClinicalTrials.gov